One biomarker. Our science. The whole story.
Scroll down to learn moreChronic inflammation is robbing the world of productive life and costing us trillions every decade.
60% of deaths worldwide are tragically linked to chronic inflammation
80% of adults over 60 suffer from at least one chronic condition
2.1B people worldwide will be over the age of 60 by 2050
$29.6T will be the expected costs of managing chronic diseases
We are bringing glycans to the world to help make personalized preventative healthcare a reality in the next 10 years.
WHAT DO WE DO AT GLYCANAGE?
Empowering Health Through Glycan Insights
Our proprietary technology, developed and validated in collaborations with Harvard, Stanford, and Karolinska, uses IgG glycans (complex sugars attached to proteins) as a real-time readout of the immune system and chronic inflammation.
Unlike genetic or epigenetic tests, glycans capture dynamic changes in health within weeks, enabling you to measure the actual impact of your habits and course-correct before minor imbalances turn into chronic issues.
FOUNDERS
Meet the People Behind GlycanAge
Our vision is driven by a team of dedicated individuals, from our core operational team to our expert longevity specialists and esteemed science advisory board.
Together, we are committed to making glycan-based insights accessible and actionable, empowering individuals to take control of their health.
Gordan Lauc, CSO, Co-Founder
Professor Gordan Lauc is the scientific mind behind GlycanAge. After two decades of pioneering research linking glycans to inflammation and aging, he co-founded the company to bring this powerful science out of the laboratory and directly to the public.
As Chief Scientific Officer, Gordan ensures the scientific validity of the product and leads the ongoing research to uncover new insights into health and longevity.
Nikolina Lauc, CEO, Co-Founder
Nikolina is the driving force behind GlycanAge's mission to empower people to take control of their health. As CEO, she leads the company's strategy, growth, and operations.
Nikolina’s passion lies in translating complex scientific knowledge into an accessible and actionable product that helps people understand their bodies and make better lifestyle choices for a longer, healthier life.
Filip Lauc, CTO, Co-Founder
Filip is the architect of the GlycanAge digital platform. As CTO, he leads the technology and product teams responsible for transforming complex biological data into the personal, intuitive insights our customers receive.
Filip is dedicated to building a seamless user experience that makes understanding and improving your biological age straightforward and engaging.
FOUNDERS
Meet the People Behind GlycanAge
Our vision is driven by a team of dedicated individuals, from our core operational team to our expert longevity specialists and esteemed science advisory board.
Together, we are committed to making glycan-based insights accessible and actionable, empowering individuals to take control of their health.
Nikolina Lauc, CEO, Co-Founder
Nikolina is the driving force behind GlycanAge's mission to empower people to take control of their health. As CEO, she leads the company's strategy, growth, and operations.
Nikolina’s passion lies in translating complex scientific knowledge into an accessible and actionable product that helps people understand their bodies and make better lifestyle choices for a longer, healthier life.
Gordan Lauc, CSO, Co-Founder
Professor Gordan Lauc is the scientific mind behind GlycanAge. After two decades of pioneering research linking glycans to inflammation and aging, he co-founded the company to bring this powerful science out of the laboratory and directly to the public.
As Chief Scientific Officer, Gordan ensures the scientific validity of the product and leads the ongoing research to uncover new insights into health and longevity.
Filip Lauc, CTO, Co-Founder
Filip is the architect of the GlycanAge digital platform. As CTO, he leads the technology and product teams responsible for transforming complex biological data into the personal, intuitive insights our customers receive.
Filip is dedicated to building a seamless user experience that makes understanding and improving your biological age straightforward and engaging.
Board of Directors
Cameron Reynolds
Chairman of the Board
Founder and CEO of Volition RX, an experienced executive in a wide range of fields, including biotechnology.
Dr. Diane Seimetz
Board Member
Drug development and regulatory expert with 22+ years experience in the biopharmaceutical sector.
COMPANY OVERVIEW
GlycanAge In Numbers
Founded in 2019
Over €40M+ in grant funding
350+ peer-reviewed publications
30+ years of research
A GLIMPSE INTO THE FUTURE
Our Roadmap
Our journey is driven by a single, ambitious goal: to shift healthcare from a reactive to a proactive model. We believe the future of medicine lies in understanding the body's earliest signals of disease, long before symptoms appear.
Short term goals (next 12-18 months):
Menopause & hormone optimization – companion diagnostic for HRT to personalize and monitor treatment.
- GLP-1 weight loss drugs – inflammation and cardiovascular risk companion diagnostic, validated in a Novo Nordisk trial.
- Expand commercial partnerships in the UAE, US, and Europe.
Maintain leadership in glycan analysis (already processing over 83% of global human glycome datasets).
Accelerate B2B integrations with longevity clinics, hospitals, and insurers.
Long term goals (18+ months):
Establish glycans as the “HbA1c of immune health” — a routine biomarker in global clinical practice.
Expand indications to major chronic diseases (cardiovascular, autoimmune, metabolic, neurodegenerative).
Build the largest global glycan dataset linked to health outcomes to power AI-driven diagnostics and therapeutics.
Achieve regulatory approval for clinical use in key markets.
BACKED BY THE BEST
Funding Overview
Since our inception, we’ve been backed by 25+ leading health, biotech, and deep-tech
venture funds, visionary angel investors, as well as significant grant funding.
If you share our passion for shaping the future of health, we’d love to connect. Book a call
to discover more about our mission, explore our traction to date, and learn how you can be
part of our growth journey.
EXCLUSIVELY FOR OUR INVESTORS
Join Our Long-term Healthspan and Lifespan Research Program
We stand by the values we champion — proactive, preventive health — and apply them across everything we do, including how we support the investors who believe in us.
We’ve launched a dedicated research program focused on the long-term health of our supporters, currently enrolling 150+ investors, LPs, and fund managers.
The program offers 10 years of complimentary longitudinal testing paired with specialist health consultations. While it contributes valuable data to advance glycoscience, its primary goal is to support the wellbeing of those who’ve invested in our mission.
Already investing in us, but not a part of our program yet? Get in touch with us at investor-study@glycanage.com to get enrolled.
STAY INFORMED
News and Events
GlycanAge closes $8.7m funding round
18 Dec 2025GlycanAge has raised $8.7M to accelerate clinical development and expand access to glycan-based testing across hospitals and preventive care. The funding supports validation of diagnostic indications, development of lab-developed tests, and deployment of glycan testing across hospital networks in the US, Europe and the Middle East.
MoU Signed with KACST
30 Oct 2025A Memorandum of Understanding has been signed with King Abdulaziz City for Science and Technology, Saudi Arabia’s leading national research institution. The collaboration supports localisation of glycan analysis technology and contributes to the Kingdom’s Vision 2030 goals. Together we aim to advance preventive, data-driven and personalised healthcare across the region.
AI Interpretation Tool Launched
15 Sep 2025The AI Interpretation Tool has officially launched, offering real-time analysis powered by glycan science. Trained on over 200,000 samples and 300+ publications, it delivers personalised insights on biological age and health optimisation. Designed for 24/7 use, it brings expert-level interpretation directly to practitioners and individuals.
Collaboration with Clinique La Prairie
10 Jul 2025A flagship partnership has launched at Clinique La Prairie, the world-renowned medical spa in Montreux. We implemented a tailored white-label product, an exclusive chronic inflammation score and a faster turnaround time to support their elite longevity programs. This collaboration showcases how glycan-based insights elevate high-end personalised health.
Expansion into the Chinese Market
30 May 2025GlycanAge has entered the Chinese market through a new distribution agreement with GlycanCode Biotech. The partnership enables local laboratories to perform glycan analysis directly, bringing our technology closer to clinicians and consumers. This model sets the foundation for scalable expansion across one of the world’s most dynamic longevity markets.
GlycanAge Seed Round
19 Feb 2024GlycanAge has raised $4.2M in seed funding, marking a major milestone in our mission to bring glycan-based biological age testing into everyday clinical practice. The investment enables expanded laboratory capacity and deeper scientific validation. It also accelerates development of next-generation products that will power the future of personalised longevity.
Investors FAQ
Frequently Asked Questions
You asked us and we answered. If you happen to have additional questions, feel free to get in touch with us at invest@glycanage.com.
How is GlycanAge different from genetic or epigenetic tests?
Who are your competitors?
Why hasn’t big pharma or academia led this field?
What’s your regulatory position?
What’s your IP position?
STAY UPDATED
Join Our Mailing List
Be the first one to hear about our milestones, key insights, company news, and investment opportunities.